Evoke Pharma(EVOK) Stock Price Today | Quotes & News

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga17:05 ET
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
Zhitong FinanceMar 18 03:00 ET
New York Manufacturing Hits Low, Inflation Fears Rise
InvestingMar 17 08:50 ET
Earnings Update: Evoke Pharma, Inc. (NASDAQ:EVOK) Just Reported And Analysts Are Trimming Their Forecasts
Simply Wall StMar 16 09:19 ET
Q4 2024 Evoke Pharma Inc Earnings Call
Yahoo FinanceMar 14 13:44 ET
Evoke Pharma Reports Strong Revenue Growth in 2024
TipRanksMar 13 23:57 ET

Comments

Strain

Feb 14 09:49

why is this rising?

$Evoke Pharma (EVOK.US)$
anyone got any news?

Stock_Drift

Dec 20, 2024 00:24

Low Floats. 11:22am

$Evoke Pharma (EVOK.US)$ $Mainz Biomed (MYNZ.US)$ $Allarity Therapeutics (ALLR.US)$ $NLS Pharmaceutics (NLSP.US)$ $Gelteq (GELS.US)$ $Real Messenger (RMSG.US)$ $PMGC Holdings (ELAB.US)$ $DallasNews (DALN.US)$ $Avalon GloboCare (ALBT.US)$ $Psyence Biomedical (PBM.US)$ $XChange TEC (XHG.US)$ $Trio Petroleum (TPET.US)$ $PainReform (PRFX.US)$
📊⚡️📊

1

Aldo Brilianta

Dec 19, 2024 23:08

$Evoke Pharma (EVOK.US)$ wow

Trytosaveabit

Dec 19, 2024 21:47

Update

$Evoke Pharma (EVOK.US)$ Evoke Pharma Highlights GIMOTI As A Leading Solution For Gastroparesis Treatment As Domperidone Supply Ends; FDA Posts Update As Mechanism To Obtain Unapproved Domperidone Expected To Lose Supply In Early 2025
Benzinga· 2 mins ago
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025
Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to...

1

Jaguar8

Dec 19, 2024 21:34

NEWS

$Evoke Pharma (EVOK.US)$
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
Thursday, 19th December at 8:30 am
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025
Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide
SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Phar...

1

9

EVOK Evoke Pharma

Trade Overview

Capital Trend

News

Comments

Market Insights